Online inquiry

IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2503MR)

This product GTTS-WQ2503MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD3E&FOLH1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_001014986.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 2346
UniProt ID P07766; Q04609
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ2503MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15042MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ6710MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DS 1024
GTTS-WQ650MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 8c10
GTTS-WQ2570MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 479
GTTS-WQ10782MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA M-70
GTTS-WQ12447MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA NKTR-214
GTTS-WQ14659MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ14593MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SAR-650984
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW